Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Feeding | 14 | 2022 | 133 | 3.940 |
Why?
|
Product Surveillance, Postmarketing | 7 | 2019 | 110 | 2.050 |
Why?
|
Mothers | 6 | 2022 | 110 | 1.590 |
Why?
|
Maternal Health Services | 3 | 2022 | 12 | 1.560 |
Why?
|
Humans | 73 | 2022 | 18430 | 1.350 |
Why?
|
United States | 36 | 2022 | 4164 | 1.250 |
Why?
|
Infant Formula | 3 | 2016 | 11 | 1.210 |
Why?
|
Infant | 22 | 2022 | 1245 | 1.190 |
Why?
|
Influenza Vaccines | 5 | 2022 | 290 | 1.090 |
Why?
|
Chickenpox Vaccine | 3 | 2019 | 101 | 1.060 |
Why?
|
Hospitals | 3 | 2018 | 80 | 1.060 |
Why?
|
Female | 49 | 2022 | 13136 | 1.050 |
Why?
|
Executive Function | 7 | 2022 | 22 | 1.010 |
Why?
|
Child | 22 | 2022 | 2571 | 0.910 |
Why?
|
Measles-Mumps-Rubella Vaccine | 4 | 2019 | 67 | 0.890 |
Why?
|
Feeding Behavior | 4 | 2022 | 168 | 0.870 |
Why?
|
Child, Preschool | 23 | 2022 | 1478 | 0.870 |
Why?
|
Trichomonas Infections | 1 | 2022 | 1 | 0.860 |
Why?
|
Sex Offenses | 1 | 2022 | 8 | 0.860 |
Why?
|
Male | 36 | 2022 | 10440 | 0.840 |
Why?
|
Sexually Transmitted Diseases | 1 | 2022 | 55 | 0.830 |
Why?
|
Hepatitis B | 1 | 2022 | 43 | 0.830 |
Why?
|
Guillain-Barre Syndrome | 1 | 2022 | 19 | 0.810 |
Why?
|
Seizures, Febrile | 2 | 2019 | 47 | 0.760 |
Why?
|
Maternal Behavior | 2 | 2018 | 13 | 0.760 |
Why?
|
Herpes Zoster Vaccine | 1 | 2022 | 64 | 0.750 |
Why?
|
Population Surveillance | 7 | 2019 | 271 | 0.740 |
Why?
|
Herpes Zoster | 1 | 2022 | 88 | 0.730 |
Why?
|
Vaccines, Combined | 3 | 2019 | 91 | 0.710 |
Why?
|
Infant, Newborn | 11 | 2020 | 872 | 0.690 |
Why?
|
Pregnancy | 13 | 2022 | 1516 | 0.680 |
Why?
|
Drug Monitoring | 1 | 2019 | 22 | 0.670 |
Why?
|
Rubella | 1 | 2019 | 6 | 0.670 |
Why?
|
Mumps | 1 | 2019 | 12 | 0.660 |
Why?
|
Chickenpox | 1 | 2019 | 38 | 0.650 |
Why?
|
Measles | 1 | 2019 | 26 | 0.650 |
Why?
|
Influenza, Human | 3 | 2017 | 282 | 0.630 |
Why?
|
Physicians | 1 | 2019 | 141 | 0.610 |
Why?
|
Epidemiologic Research Design | 3 | 2013 | 24 | 0.600 |
Why?
|
Campylobacter | 3 | 2007 | 3 | 0.590 |
Why?
|
Campylobacter Infections | 3 | 2007 | 3 | 0.590 |
Why?
|
Pediatric Obesity | 2 | 2017 | 80 | 0.580 |
Why?
|
Adult | 17 | 2022 | 7910 | 0.580 |
Why?
|
Adolescent | 16 | 2022 | 3798 | 0.560 |
Why?
|
Public Opinion | 1 | 2016 | 6 | 0.560 |
Why?
|
Poliovirus Vaccine, Inactivated | 2 | 2014 | 21 | 0.540 |
Why?
|
Diphtheria-Tetanus-Pertussis Vaccine | 2 | 2014 | 30 | 0.540 |
Why?
|
Dietary Supplements | 1 | 2016 | 88 | 0.540 |
Why?
|
Vaccines | 5 | 2022 | 222 | 0.530 |
Why?
|
Outcome Assessment (Health Care) | 2 | 2016 | 254 | 0.520 |
Why?
|
Vaccination | 5 | 2022 | 674 | 0.520 |
Why?
|
Cohort Studies | 14 | 2022 | 2672 | 0.510 |
Why?
|
Health Care Surveys | 5 | 2020 | 247 | 0.500 |
Why?
|
Statistics as Topic | 2 | 2013 | 66 | 0.500 |
Why?
|
Directive Counseling | 1 | 2015 | 25 | 0.490 |
Why?
|
Drug Resistance, Bacterial | 5 | 2007 | 15 | 0.480 |
Why?
|
Patient Discharge | 2 | 2018 | 153 | 0.480 |
Why?
|
Resilience, Psychological | 1 | 2014 | 8 | 0.470 |
Why?
|
Weight Reduction Programs | 1 | 2015 | 60 | 0.460 |
Why?
|
Social Environment | 1 | 2014 | 90 | 0.450 |
Why?
|
Logistic Models | 6 | 2020 | 962 | 0.450 |
Why?
|
Observational Studies as Topic | 3 | 2022 | 49 | 0.450 |
Why?
|
Longitudinal Studies | 10 | 2022 | 724 | 0.430 |
Why?
|
Haemophilus Vaccines | 1 | 2013 | 25 | 0.430 |
Why?
|
Comparative Effectiveness Research | 1 | 2013 | 77 | 0.430 |
Why?
|
Mortality | 1 | 2013 | 123 | 0.420 |
Why?
|
Vaccines, Conjugate | 2 | 2013 | 66 | 0.420 |
Why?
|
Immunization Programs | 2 | 2009 | 68 | 0.410 |
Why?
|
Equipment Safety | 1 | 2011 | 2 | 0.400 |
Why?
|
Intention | 3 | 2022 | 28 | 0.400 |
Why?
|
Parasympatholytics | 1 | 2011 | 1 | 0.390 |
Why?
|
Escherichia coli O157 | 1 | 2011 | 1 | 0.390 |
Why?
|
Shiga Toxins | 1 | 2011 | 1 | 0.390 |
Why?
|
Hemolytic-Uremic Syndrome | 1 | 2011 | 2 | 0.390 |
Why?
|
Anti-Bacterial Agents | 2 | 2011 | 142 | 0.390 |
Why?
|
Escherichia coli Infections | 1 | 2011 | 6 | 0.390 |
Why?
|
Postnatal Care | 4 | 2022 | 22 | 0.390 |
Why?
|
Electronic Nicotine Delivery Systems | 2 | 2022 | 32 | 0.380 |
Why?
|
Ethnic Groups | 4 | 2021 | 501 | 0.380 |
Why?
|
Calcinosis | 3 | 2006 | 40 | 0.380 |
Why?
|
Young Adult | 7 | 2021 | 2518 | 0.370 |
Why?
|
Atherosclerosis | 2 | 2014 | 51 | 0.370 |
Why?
|
Aged | 10 | 2022 | 6417 | 0.350 |
Why?
|
Adolescent Behavior | 2 | 2022 | 129 | 0.350 |
Why?
|
Infant Care | 2 | 2020 | 6 | 0.350 |
Why?
|
Hepatitis A Vaccines | 1 | 2009 | 14 | 0.340 |
Why?
|
Coronary Artery Disease | 3 | 2005 | 133 | 0.340 |
Why?
|
Time Factors | 5 | 2018 | 1136 | 0.330 |
Why?
|
Hepatitis B Vaccines | 1 | 2009 | 46 | 0.330 |
Why?
|
Health Personnel | 2 | 2022 | 126 | 0.320 |
Why?
|
Community-Acquired Infections | 1 | 2008 | 24 | 0.310 |
Why?
|
Food Service, Hospital | 1 | 2008 | 1 | 0.310 |
Why?
|
Foodborne Diseases | 1 | 2008 | 5 | 0.310 |
Why?
|
Primary Health Care | 1 | 2015 | 848 | 0.310 |
Why?
|
Food Handling | 1 | 2008 | 6 | 0.310 |
Why?
|
Homes for the Aged | 1 | 2008 | 6 | 0.310 |
Why?
|
Nursing Homes | 1 | 2008 | 10 | 0.310 |
Why?
|
Pneumococcal Infections | 1 | 2008 | 53 | 0.310 |
Why?
|
Ciprofloxacin | 2 | 2004 | 2 | 0.300 |
Why?
|
Pneumonia | 1 | 2008 | 56 | 0.300 |
Why?
|
Pneumococcal Vaccines | 1 | 2008 | 80 | 0.300 |
Why?
|
Retrospective Studies | 7 | 2022 | 2550 | 0.300 |
Why?
|
Anti-Infective Agents | 2 | 2004 | 15 | 0.300 |
Why?
|
Feeding and Eating Disorders | 2 | 2017 | 17 | 0.290 |
Why?
|
Poultry Diseases | 1 | 2007 | 1 | 0.290 |
Why?
|
Fluoroquinolones | 1 | 2007 | 7 | 0.290 |
Why?
|
Electronic Health Records | 2 | 2014 | 747 | 0.290 |
Why?
|
Tomography, X-Ray Computed | 2 | 2005 | 208 | 0.280 |
Why?
|
Adverse Drug Reaction Reporting Systems | 3 | 2019 | 101 | 0.280 |
Why?
|
Multivariate Analysis | 3 | 2018 | 598 | 0.280 |
Why?
|
Diphtheria-Tetanus-acellular Pertussis Vaccines | 2 | 2020 | 95 | 0.280 |
Why?
|
Databases, Factual | 3 | 2013 | 327 | 0.280 |
Why?
|
Sphingomyelins | 1 | 2006 | 1 | 0.270 |
Why?
|
Medication Adherence | 1 | 2009 | 267 | 0.270 |
Why?
|
Zika Virus Infection | 2 | 2016 | 4 | 0.270 |
Why?
|
Surveys and Questionnaires | 3 | 2017 | 1389 | 0.260 |
Why?
|
Animals | 5 | 2016 | 261 | 0.260 |
Why?
|
Bias | 2 | 2020 | 111 | 0.260 |
Why?
|
Durapatite | 1 | 2005 | 1 | 0.260 |
Why?
|
Tomography, Spiral Computed | 1 | 2005 | 1 | 0.260 |
Why?
|
Nutritional Status | 2 | 2022 | 30 | 0.250 |
Why?
|
Risk Factors | 8 | 2017 | 3449 | 0.250 |
Why?
|
Health Promotion | 2 | 2018 | 294 | 0.250 |
Why?
|
Models, Statistical | 3 | 2014 | 185 | 0.250 |
Why?
|
Diarrhea | 1 | 2004 | 13 | 0.240 |
Why?
|
Risk Assessment | 5 | 2018 | 1143 | 0.240 |
Why?
|
Odds Ratio | 4 | 2018 | 701 | 0.240 |
Why?
|
Demography | 3 | 2016 | 108 | 0.240 |
Why?
|
Immunization Schedule | 3 | 2014 | 133 | 0.240 |
Why?
|
Infant Nutritional Physiological Phenomena | 2 | 2020 | 6 | 0.230 |
Why?
|
Middle Aged | 11 | 2021 | 8284 | 0.230 |
Why?
|
Child Development | 2 | 2014 | 52 | 0.220 |
Why?
|
Prevalence | 5 | 2015 | 911 | 0.210 |
Why?
|
Socioeconomic Factors | 2 | 2016 | 673 | 0.210 |
Why?
|
HIV | 1 | 2022 | 26 | 0.210 |
Why?
|
Cross-Sectional Studies | 4 | 2022 | 1360 | 0.210 |
Why?
|
Pericarditis | 1 | 2022 | 14 | 0.210 |
Why?
|
Research Design | 4 | 2016 | 402 | 0.210 |
Why?
|
Emergency Service, Hospital | 2 | 2022 | 382 | 0.210 |
Why?
|
Cataplexy | 1 | 2022 | 5 | 0.210 |
Why?
|
Narcolepsy | 1 | 2022 | 6 | 0.210 |
Why?
|
Myocarditis | 1 | 2022 | 18 | 0.210 |
Why?
|
Obesity | 2 | 2021 | 855 | 0.210 |
Why?
|
Bell Palsy | 1 | 2022 | 17 | 0.200 |
Why?
|
Thrombocytopenia | 1 | 2022 | 15 | 0.200 |
Why?
|
Confounding Factors (Epidemiology) | 3 | 2012 | 99 | 0.200 |
Why?
|
Vaccines, Synthetic | 1 | 2022 | 43 | 0.200 |
Why?
|
Aged, 80 and over | 5 | 2014 | 2003 | 0.200 |
Why?
|
Case-Control Studies | 5 | 2020 | 1173 | 0.200 |
Why?
|
Public Health | 3 | 2009 | 82 | 0.200 |
Why?
|
Cardiovascular Abnormalities | 1 | 2021 | 1 | 0.200 |
Why?
|
Adolescent Health | 1 | 2021 | 6 | 0.190 |
Why?
|
Evidence-Based Medicine | 2 | 2016 | 195 | 0.190 |
Why?
|
Pregnancy Complications, Infectious | 2 | 2020 | 142 | 0.190 |
Why?
|
Vaping | 1 | 2021 | 17 | 0.190 |
Why?
|
Tobacco Products | 1 | 2021 | 17 | 0.190 |
Why?
|
Child Health | 1 | 2021 | 34 | 0.190 |
Why?
|
Database Management Systems | 1 | 2020 | 15 | 0.190 |
Why?
|
Milk, Human | 2 | 2020 | 7 | 0.190 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 2 | 2019 | 116 | 0.190 |
Why?
|
Vaccination Coverage | 1 | 2021 | 45 | 0.190 |
Why?
|
Managed Care Programs | 2 | 2013 | 347 | 0.190 |
Why?
|
Problem Behavior | 1 | 2020 | 4 | 0.190 |
Why?
|
Stillbirth | 1 | 2020 | 30 | 0.190 |
Why?
|
Child Behavior Disorders | 1 | 2020 | 18 | 0.180 |
Why?
|
Medicare | 1 | 2022 | 214 | 0.180 |
Why?
|
Prospective Studies | 3 | 2014 | 1314 | 0.180 |
Why?
|
Body Mass Index | 3 | 2017 | 974 | 0.180 |
Why?
|
Proportional Hazards Models | 2 | 2020 | 743 | 0.180 |
Why?
|
Propensity Score | 1 | 2020 | 94 | 0.180 |
Why?
|
Practice Patterns, Physicians' | 2 | 2015 | 350 | 0.180 |
Why?
|
Poverty | 2 | 2021 | 182 | 0.170 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2021 | 124 | 0.170 |
Why?
|
Food Packaging | 1 | 2019 | 2 | 0.170 |
Why?
|
Recommended Dietary Allowances | 1 | 2019 | 2 | 0.170 |
Why?
|
Infant Food | 1 | 2019 | 8 | 0.170 |
Why?
|
Nutritive Value | 1 | 2019 | 11 | 0.170 |
Why?
|
Dietary Sugars | 1 | 2019 | 6 | 0.170 |
Why?
|
Databases, Pharmaceutical | 1 | 2019 | 6 | 0.170 |
Why?
|
Insurance, Health | 1 | 2021 | 217 | 0.170 |
Why?
|
Pediatricians | 1 | 2019 | 15 | 0.170 |
Why?
|
Severity of Illness Index | 1 | 2021 | 476 | 0.170 |
Why?
|
Continental Population Groups | 2 | 2021 | 315 | 0.170 |
Why?
|
Energy Intake | 1 | 2019 | 103 | 0.170 |
Why?
|
Reproductive Techniques, Assisted | 1 | 2018 | 2 | 0.160 |
Why?
|
Infertility, Female | 1 | 2018 | 11 | 0.160 |
Why?
|
Hospitals, Maternity | 1 | 2018 | 2 | 0.160 |
Why?
|
Rooming-in Care | 1 | 2018 | 1 | 0.160 |
Why?
|
Health Facilities | 1 | 2018 | 18 | 0.150 |
Why?
|
Selection Bias | 1 | 2017 | 24 | 0.150 |
Why?
|
Immunogenicity, Vaccine | 1 | 2017 | 12 | 0.150 |
Why?
|
Communicable Disease Control | 1 | 2017 | 19 | 0.150 |
Why?
|
Extraversion (Psychology) | 1 | 2017 | 1 | 0.150 |
Why?
|
Substance-Related Disorders | 1 | 2022 | 439 | 0.150 |
Why?
|
Mother-Child Relations | 1 | 2017 | 14 | 0.150 |
Why?
|
Hotlines | 1 | 2017 | 16 | 0.140 |
Why?
|
Referral and Consultation | 1 | 2018 | 180 | 0.140 |
Why?
|
Cognition | 2 | 2020 | 82 | 0.140 |
Why?
|
Oral Health | 1 | 2017 | 21 | 0.140 |
Why?
|
Overweight | 2 | 2016 | 276 | 0.140 |
Why?
|
Practice Guidelines as Topic | 2 | 2016 | 333 | 0.140 |
Why?
|
Smoking Prevention | 1 | 2017 | 55 | 0.140 |
Why?
|
Data Interpretation, Statistical | 2 | 2009 | 83 | 0.140 |
Why?
|
Sleep Wake Disorders | 1 | 2016 | 38 | 0.140 |
Why?
|
Anxiety | 1 | 2017 | 156 | 0.130 |
Why?
|
Chickens | 2 | 2007 | 6 | 0.130 |
Why?
|
Incidence | 4 | 2022 | 1314 | 0.130 |
Why?
|
Poisson Distribution | 2 | 2013 | 94 | 0.130 |
Why?
|
Lactation | 1 | 2016 | 50 | 0.130 |
Why?
|
Food Microbiology | 2 | 2005 | 2 | 0.130 |
Why?
|
Georgia | 1 | 2015 | 25 | 0.120 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2017 | 392 | 0.120 |
Why?
|
Memory, Short-Term | 1 | 2014 | 1 | 0.120 |
Why?
|
Serial Learning | 1 | 2014 | 1 | 0.120 |
Why?
|
Endothelium, Vascular | 1 | 2014 | 5 | 0.120 |
Why?
|
Vasodilation | 1 | 2014 | 8 | 0.120 |
Why?
|
Brachial Artery | 1 | 2014 | 6 | 0.120 |
Why?
|
Seizures | 1 | 2014 | 30 | 0.120 |
Why?
|
Mental Recall | 1 | 2014 | 31 | 0.120 |
Why?
|
Biometry | 1 | 2014 | 13 | 0.120 |
Why?
|
Algorithms | 3 | 2017 | 241 | 0.120 |
Why?
|
Safety | 1 | 2014 | 45 | 0.110 |
Why?
|
Inflammation | 1 | 2014 | 63 | 0.110 |
Why?
|
African Americans | 1 | 2017 | 490 | 0.110 |
Why?
|
Epidemiologic Factors | 1 | 2013 | 4 | 0.110 |
Why?
|
Alcohol Drinking | 1 | 2017 | 375 | 0.110 |
Why?
|
Microbial Sensitivity Tests | 4 | 2006 | 8 | 0.110 |
Why?
|
Attitude of Health Personnel | 1 | 2015 | 226 | 0.110 |
Why?
|
Biomarkers | 1 | 2014 | 308 | 0.110 |
Why?
|
Inhibition (Psychology) | 1 | 2012 | 1 | 0.110 |
Why?
|
Whooping Cough | 1 | 2013 | 75 | 0.110 |
Why?
|
Age Factors | 4 | 2019 | 965 | 0.100 |
Why?
|
Adaptation, Psychological | 1 | 2012 | 82 | 0.100 |
Why?
|
Washington | 1 | 2013 | 388 | 0.100 |
Why?
|
Depression | 1 | 2017 | 518 | 0.100 |
Why?
|
Device Approval | 1 | 2011 | 2 | 0.100 |
Why?
|
Clinical Trials, Phase IV as Topic | 1 | 2011 | 3 | 0.100 |
Why?
|
Adamantane | 1 | 2012 | 6 | 0.100 |
Why?
|
Dipeptides | 1 | 2012 | 6 | 0.100 |
Why?
|
Biostatistics | 1 | 2011 | 10 | 0.100 |
Why?
|
Data Mining | 1 | 2011 | 20 | 0.100 |
Why?
|
Health Services | 1 | 2013 | 117 | 0.100 |
Why?
|
Diphenoxylate | 1 | 2011 | 1 | 0.100 |
Why?
|
Loperamide | 1 | 2011 | 1 | 0.100 |
Why?
|
United States Food and Drug Administration | 2 | 2012 | 36 | 0.100 |
Why?
|
Drug Utilization | 2 | 2013 | 134 | 0.100 |
Why?
|
Hypertension | 1 | 2016 | 524 | 0.100 |
Why?
|
Risk | 1 | 2013 | 552 | 0.100 |
Why?
|
Health Status | 1 | 2013 | 328 | 0.090 |
Why?
|
Cardiovascular Diseases | 1 | 2016 | 630 | 0.090 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2012 | 342 | 0.090 |
Why?
|
Clinical Trials as Topic | 1 | 2010 | 133 | 0.090 |
Why?
|
Regression Analysis | 2 | 2012 | 319 | 0.090 |
Why?
|
Myocardial Infarction | 1 | 2012 | 249 | 0.090 |
Why?
|
Drug Administration Schedule | 1 | 2009 | 100 | 0.080 |
Why?
|
Pandemics | 2 | 2022 | 292 | 0.080 |
Why?
|
Hypoglycemic Agents | 1 | 2012 | 288 | 0.080 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2016 | 760 | 0.080 |
Why?
|
Food Irradiation | 1 | 2008 | 1 | 0.080 |
Why?
|
Consumer Product Safety | 1 | 2008 | 2 | 0.080 |
Why?
|
Long-Term Care | 1 | 2008 | 22 | 0.080 |
Why?
|
Medicaid | 1 | 2009 | 211 | 0.080 |
Why?
|
Age Distribution | 1 | 2008 | 261 | 0.080 |
Why?
|
Drug and Narcotic Control | 1 | 2007 | 5 | 0.070 |
Why?
|
Policy Making | 1 | 2007 | 18 | 0.070 |
Why?
|
Data Collection | 1 | 2008 | 275 | 0.070 |
Why?
|
Hispanic Americans | 2 | 2020 | 428 | 0.070 |
Why?
|
Carotid Arteries | 1 | 2006 | 10 | 0.070 |
Why?
|
Coronary Vessels | 1 | 2006 | 15 | 0.070 |
Why?
|
Centers for Disease Control and Prevention (U.S.) | 2 | 2016 | 33 | 0.070 |
Why?
|
Shigella | 1 | 2006 | 1 | 0.070 |
Why?
|
Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2006 | 3 | 0.070 |
Why?
|
Shigella flexneri | 1 | 2005 | 1 | 0.070 |
Why?
|
Dysentery, Bacillary | 1 | 2005 | 2 | 0.070 |
Why?
|
Lycopersicon esculentum | 1 | 2005 | 4 | 0.070 |
Why?
|
Blood Pressure Determination | 1 | 2006 | 58 | 0.070 |
Why?
|
Chi-Square Distribution | 1 | 2006 | 160 | 0.070 |
Why?
|
beta-Lactamases | 1 | 2005 | 1 | 0.070 |
Why?
|
beta-Lactam Resistance | 1 | 2005 | 2 | 0.070 |
Why?
|
Enterobacteriaceae | 1 | 2005 | 3 | 0.070 |
Why?
|
Disease Outbreaks | 1 | 2005 | 39 | 0.070 |
Why?
|
Cephalosporins | 1 | 2005 | 8 | 0.070 |
Why?
|
Phantoms, Imaging | 1 | 2005 | 4 | 0.060 |
Why?
|
Calibration | 1 | 2005 | 8 | 0.060 |
Why?
|
Predictive Value of Tests | 1 | 2006 | 365 | 0.060 |
Why?
|
Treatment Outcome | 1 | 2009 | 1296 | 0.060 |
Why?
|
Patient Acceptance of Health Care | 2 | 2022 | 407 | 0.060 |
Why?
|
Computer Simulation | 2 | 2017 | 85 | 0.060 |
Why?
|
Sensitivity and Specificity | 1 | 2005 | 321 | 0.060 |
Why?
|
Reaction Time | 2 | 2014 | 3 | 0.060 |
Why?
|
Animals, Domestic | 1 | 2003 | 4 | 0.050 |
Why?
|
Altruism | 1 | 2022 | 1 | 0.050 |
Why?
|
Aggression | 1 | 2022 | 19 | 0.050 |
Why?
|
RNA, Messenger | 1 | 2022 | 80 | 0.050 |
Why?
|
Peer Group | 1 | 2022 | 48 | 0.050 |
Why?
|
Midwestern United States | 1 | 2021 | 4 | 0.050 |
Why?
|
Respiration, Artificial | 1 | 2021 | 38 | 0.050 |
Why?
|
Intensive Care Units | 1 | 2021 | 106 | 0.040 |
Why?
|
Health Status Disparities | 1 | 2021 | 153 | 0.040 |
Why?
|
Follow-Up Studies | 2 | 2014 | 1269 | 0.040 |
Why?
|
Premature Birth | 1 | 2021 | 138 | 0.040 |
Why?
|
Comorbidity | 1 | 2021 | 619 | 0.040 |
Why?
|
Public Health Surveillance | 1 | 2018 | 45 | 0.040 |
Why?
|
Clinical Studies as Topic | 1 | 2017 | 1 | 0.040 |
Why?
|
Chronic Disease | 1 | 2021 | 468 | 0.040 |
Why?
|
Health Surveys | 1 | 2018 | 269 | 0.040 |
Why?
|
Patient Outcome Assessment | 1 | 2017 | 29 | 0.040 |
Why?
|
Dental Care | 1 | 2017 | 19 | 0.040 |
Why?
|
Patient Education as Topic | 1 | 2018 | 214 | 0.040 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2017 | 129 | 0.040 |
Why?
|
Sex Distribution | 1 | 2017 | 198 | 0.030 |
Why?
|
Insect Vectors | 1 | 2016 | 1 | 0.030 |
Why?
|
Culicidae | 1 | 2016 | 1 | 0.030 |
Why?
|
Conjunctivitis | 1 | 2016 | 2 | 0.030 |
Why?
|
Arthralgia | 1 | 2016 | 3 | 0.030 |
Why?
|
Exanthema | 1 | 2016 | 8 | 0.030 |
Why?
|
Travel | 1 | 2016 | 10 | 0.030 |
Why?
|
Diagnosis, Differential | 1 | 2016 | 61 | 0.030 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2016 | 22 | 0.030 |
Why?
|
Fever | 1 | 2016 | 60 | 0.030 |
Why?
|
Metabolic Syndrome | 1 | 2016 | 80 | 0.030 |
Why?
|
Schools | 1 | 2016 | 89 | 0.030 |
Why?
|
Hospitalization | 1 | 2021 | 847 | 0.030 |
Why?
|
Dyslipidemias | 1 | 2016 | 65 | 0.030 |
Why?
|
Reproducibility of Results | 1 | 2016 | 399 | 0.030 |
Why?
|
Smoking Cessation | 1 | 2017 | 199 | 0.030 |
Why?
|
Biomarkers, Pharmacological | 1 | 2015 | 6 | 0.030 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2021 | 567 | 0.030 |
Why?
|
European Continental Ancestry Group | 1 | 2017 | 554 | 0.030 |
Why?
|
Ultrasonography | 1 | 2014 | 36 | 0.030 |
Why?
|
Neuropsychological Tests | 1 | 2014 | 38 | 0.030 |
Why?
|
Cytokines | 1 | 2014 | 30 | 0.030 |
Why?
|
C-Reactive Protein | 1 | 2014 | 58 | 0.030 |
Why?
|
Vaccines, Inactivated | 1 | 2014 | 70 | 0.030 |
Why?
|
Photic Stimulation | 1 | 2012 | 2 | 0.030 |
Why?
|
Factor Analysis, Statistical | 1 | 2012 | 36 | 0.030 |
Why?
|
Drug Approval | 1 | 2012 | 14 | 0.030 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 1 | 2012 | 8 | 0.030 |
Why?
|
Diabetes, Gestational | 1 | 2016 | 339 | 0.020 |
Why?
|
Health Behavior | 1 | 2013 | 374 | 0.020 |
Why?
|
Ampicillin Resistance | 1 | 2006 | 1 | 0.020 |
Why?
|
Trimethoprim Resistance | 1 | 2006 | 1 | 0.020 |
Why?
|
Drug Resistance, Multiple | 1 | 2006 | 1 | 0.020 |
Why?
|
Ampicillin | 1 | 2006 | 2 | 0.020 |
Why?
|
New York | 1 | 2005 | 22 | 0.020 |
Why?
|
Restaurants | 1 | 2005 | 17 | 0.020 |
Why?
|
Isoelectric Focusing | 1 | 2005 | 1 | 0.020 |
Why?
|
Quality Control | 1 | 2005 | 48 | 0.020 |
Why?
|
Clinical Protocols | 1 | 2005 | 45 | 0.020 |
Why?
|
Goals | 1 | 2002 | 33 | 0.010 |
Why?
|
Epidemiologic Methods | 1 | 2002 | 87 | 0.010 |
Why?
|
Disease Progression | 1 | 2002 | 271 | 0.010 |
Why?
|